NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis $9.69 -0.95 (-8.93%) Closing price 04:00 PM EasternExtended Trading$9.68 0.00 (-0.05%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Xencor Stock (NASDAQ:XNCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xencor alerts:Sign Up Key Stats Today's Range$9.65▼$10.5950-Day Range$10.64▼$20.6752-Week Range$9.65▼$27.24Volume954,815 shsAverage Volume597,927 shsMarket Capitalization$682.78 millionP/E RatioN/ADividend YieldN/APrice Target$34.38Consensus RatingBuy Company OverviewXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More… Remove Ads Xencor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreXNCR MarketRank™: Xencor scored higher than 74% of companies evaluated by MarketBeat, and ranked 258th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXencor has only been the subject of 1 research reports in the past 90 days.Read more about Xencor's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.68) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.15% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Xencor has recently increased by 8.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.24 Percentage of Shares Shorted9.15% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Xencor has recently increased by 8.20%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.62 News SentimentXencor has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xencor this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Xencor to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.23% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Stock News HeadlinesAnalysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.38March 28, 2025 | americanbankingnews.comBarclays Reaffirms Their Sell Rating on Xencor (XNCR)March 1, 2025 | markets.businessinsider.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 1, 2025 | Porter & Company (Ad)Xencor price target lowered to $32 from $34 at RBC CapitalMarch 1, 2025 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Xencor (XNCR) and Merus (MRUS)February 28, 2025 | markets.businessinsider.comXencor reports Q4 EPS ( 62c), consensus (78c)February 27, 2025 | markets.businessinsider.comXencor sees ending FY25 with $535M -$585M in cashFebruary 27, 2025 | markets.businessinsider.comXencor Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | businesswire.comSee More Headlines XNCR Stock Analysis - Frequently Asked Questions How have XNCR shares performed this year? Xencor's stock was trading at $22.98 on January 1st, 2025. Since then, XNCR shares have decreased by 57.8% and is now trading at $9.69. View the best growth stocks for 2025 here. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. The biopharmaceutical company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative trailing twelve-month return on equity of 30.92% and a negative net margin of 232.77%. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings2/27/2025Today4/01/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XNCR CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$34.38 High Stock Price Target$40.00 Low Stock Price Target$28.00 Potential Upside/Downside+254.9%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-232.77% Pretax Margin-229.85% Return on Equity-30.92% Return on Assets-21.74% Debt Debt-to-Equity Ratio0.01 Current Ratio6.23 Quick Ratio6.23 Sales & Book Value Annual Sales$110.49 million Price / Sales6.18 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book0.88Miscellaneous Outstanding Shares70,462,000Free Float66,322,000Market Cap$682.42 million OptionableOptionable Beta0.74 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:XNCR) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.